LOCALIZED HERPES ZOSTER IN IMMUNOCOMPROMISED PATIENTS

免疫功能低下患者的局限性带状疱疹

• 批准号: 3738979
• 负责人: RICHARD J. WHITLEY
• 金额: --
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3738979
• 关键词: acyclovir; antiviral agents; clinical trials; drug administration rate /duration; drug screening /evaluation; human subject; human therapy evaluation; immunodeficiency; microorganism disease chemotherapy; shingles; varicella zoster virus

This is a randomized, double-blind, controlled trial to compare the efficacy of BV-ara-U (40mg/d) vs acyclovir (800mg five times daily) in the treatment of acute localized, non-trigeminal zoster in immunocompromised patients.

这是一项随机，双盲，对照试验，以比较 BV-ARA-U（40mg/d）与Acyclovir（每天800mg）的功效 在急性局部非三角式带状吊带上的处理 免疫功能低下的患者。